{"id":3985,"date":"2017-07-25T11:36:15","date_gmt":"2017-07-25T11:36:15","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=3985"},"modified":"2017-07-25T11:36:15","modified_gmt":"2017-07-25T11:36:15","slug":"amb-2017-51-53-infliximab-versus-biosimilar-ct-p13","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/","title":{"rendered":"Infliximab versus Biosimilar CT-P13"},"content":{"rendered":"<p>\u00a0AMB 2017, 51, 53\u00a0 Infliximab versus Biosimilar CT-P13 Fazit: Eine norwegische Studie zeigt, dass Patienten, die im Rahmen zugelassener Indikationen mit dem TNF-\u03b1-Hemmer Infliximab behandelt wurden, bei der Umstellung auf das preisg\u00fcnstigere Biosimilar CT-P13 hinsichtlich Wirksamkeit und Nebenwirkungen keine Nachteile hatten.\u00a0Bitte abonnieren oder Kennlernartikel anfordern \u2013&gt; &nbsp; Alle Artikel zum Schlagwort: Biosimilars, Infliximab versus Biosimilar [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0AMB 2017, 51, 53\u00a0 Infliximab versus Biosimilar CT-P13 Fazit: Eine norwegische Studie zeigt, dass Patienten, die im Rahmen zugelassener Indikationen mit dem TNF-\u03b1-Hemmer Infliximab behandelt wurden, bei der Umstellung auf das preisg\u00fcnstigere Biosimilar CT-P13 hinsichtlich Wirksamkeit und Nebenwirkungen keine Nachteile hatten.\u00a0Bitte abonnieren oder Kennlernartikel anfordern \u2013&gt; &nbsp; Alle Artikel zum Schlagwort: Biosimilars, Infliximab versus Biosimilar [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[2705,2159,291,292,650,177,2699,2146,2704,652,2701,2702,2703,212,2700,378,2157,2160,2161,381,382,383,2162,384,385],"class_list":["post-3985","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-ankylosierende-spondylitis","tag-biologika","tag-biopharmazeutika","tag-biosimilars","tag-chronisch-entzuendliche-darmerkrankungen","tag-colitis-ulcerosa","tag-ct-p13","tag-infliximab","tag-m-bechterew","tag-m-crohn","tag-nor-switch-studie","tag-planetas-studie","tag-planetra-studie","tag-psoriasis","tag-psoriasis-arthritis","tag-rheumatoide-arthritis","tag-spondylarthritis","tag-tnf-alpha-antagonisten","tag-tnf-alpha-antikoerper","tag-tnf-alpha-blocker","tag-tnf-alpha-hemmer","tag-tumor-nekrose-faktor-antagonisten","tag-tumor-nekrose-faktor-antikoerper","tag-tumor-nekrose-faktor-blocker","tag-tumor-nekrose-faktor-hemmer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Effektivit\u00e4t hitzestabilen kosteng\u00fcnstigen Rotavirus-Impfstoffs<\/title>\n<meta name=\"description\" content=\"Effektivit\u00e4t eines oralen hitzestabilen und kosteng\u00fcnstigen Rotavirus-Impfstoffs im Niger. Lesen Sie hier den gesamten Beitrage der abonnieren Sie diesen Artikel\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Effektivit\u00e4t hitzestabilen kosteng\u00fcnstigen Rotavirus-Impfstoffs\" \/>\n<meta property=\"og:description\" content=\"Effektivit\u00e4t eines oralen hitzestabilen und kosteng\u00fcnstigen Rotavirus-Impfstoffs im Niger. Lesen Sie hier den gesamten Beitrage der abonnieren Sie diesen Artikel\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2017-07-25T11:36:15+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Infliximab versus Biosimilar CT-P13\",\"datePublished\":\"2017-07-25T11:36:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\\\/\"},\"wordCount\":152,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"keywords\":[\"Ankylosierende Spondylitis\",\"Biologika\",\"Biopharmazeutika\",\"Biosimilars\",\"Chronisch entz\u00fcndliche Darmerkrankungen\",\"Colitis ulcerosa\",\"CT-P13\",\"Infliximab\",\"M. Bechterew\",\"M. Crohn\",\"NOR-SWITCH-Studie\",\"PLANETAS-Studie\",\"PLANETRA-Studie\",\"Psoriasis\",\"Psoriasis-Arthritis\",\"Rheumatoide Arthritis\",\"Spondylarthritis\",\"TNF-alpha-Antagonisten\",\"TNF-alpha-Antik\u00f6rper\",\"TNF-alpha-Blocker\",\"TNF-alpha-Hemmer\",\"Tumor-Nekrose-Faktor-Antagonisten\",\"Tumor-Nekrose-Faktor-Antik\u00f6rper\",\"Tumor-Nekrose-Faktor-Blocker\",\"Tumor-Nekrose-Faktor-Hemmer\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\\\/\",\"name\":\"Effektivit\u00e4t hitzestabilen kosteng\u00fcnstigen Rotavirus-Impfstoffs\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"datePublished\":\"2017-07-25T11:36:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"Effektivit\u00e4t eines oralen hitzestabilen und kosteng\u00fcnstigen Rotavirus-Impfstoffs im Niger. Lesen Sie hier den gesamten Beitrage der abonnieren Sie diesen Artikel\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infliximab versus Biosimilar CT-P13\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Effektivit\u00e4t hitzestabilen kosteng\u00fcnstigen Rotavirus-Impfstoffs","description":"Effektivit\u00e4t eines oralen hitzestabilen und kosteng\u00fcnstigen Rotavirus-Impfstoffs im Niger. Lesen Sie hier den gesamten Beitrage der abonnieren Sie diesen Artikel","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/","og_locale":"de_DE","og_type":"article","og_title":"Effektivit\u00e4t hitzestabilen kosteng\u00fcnstigen Rotavirus-Impfstoffs","og_description":"Effektivit\u00e4t eines oralen hitzestabilen und kosteng\u00fcnstigen Rotavirus-Impfstoffs im Niger. Lesen Sie hier den gesamten Beitrage der abonnieren Sie diesen Artikel","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2017-07-25T11:36:15+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Infliximab versus Biosimilar CT-P13","datePublished":"2017-07-25T11:36:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/"},"wordCount":152,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","keywords":["Ankylosierende Spondylitis","Biologika","Biopharmazeutika","Biosimilars","Chronisch entz\u00fcndliche Darmerkrankungen","Colitis ulcerosa","CT-P13","Infliximab","M. Bechterew","M. Crohn","NOR-SWITCH-Studie","PLANETAS-Studie","PLANETRA-Studie","Psoriasis","Psoriasis-Arthritis","Rheumatoide Arthritis","Spondylarthritis","TNF-alpha-Antagonisten","TNF-alpha-Antik\u00f6rper","TNF-alpha-Blocker","TNF-alpha-Hemmer","Tumor-Nekrose-Faktor-Antagonisten","Tumor-Nekrose-Faktor-Antik\u00f6rper","Tumor-Nekrose-Faktor-Blocker","Tumor-Nekrose-Faktor-Hemmer"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/","name":"Effektivit\u00e4t hitzestabilen kosteng\u00fcnstigen Rotavirus-Impfstoffs","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","datePublished":"2017-07-25T11:36:15+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"Effektivit\u00e4t eines oralen hitzestabilen und kosteng\u00fcnstigen Rotavirus-Impfstoffs im Niger. Lesen Sie hier den gesamten Beitrage der abonnieren Sie diesen Artikel","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/amb-2017-51-53-infliximab-versus-biosimilar-ct-p13\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Infliximab versus Biosimilar CT-P13"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=3985"}],"version-history":[{"count":1,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3985\/revisions"}],"predecessor-version":[{"id":3986,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3985\/revisions\/3986"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=3985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=3985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=3985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}